%0 Journal Article
%T Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database.
%A Klar M
%A Plett H
%A Harter P
%A Heitz F
%A Kommoss S
%A Hartkopf AD
%A Grube M
%A Roser E
%A Sehouli J
%A Braicu I
%A Czogalla B
%A Burges A
%A Bossart M
%A Hasanov MF
%A Link T
%A Staebler A
%A Mayr D
%A Buderath P
%A Hasenburg A
%J J Surg Oncol
%V 128
%N 1
%D Jul 2023 28
%M 36975108
%F 2.885
%R 10.1002/jso.27248
%X <B>BACKGROUND: </B>Malignant sex cord-stromal cell tumours (SCST) account for only 7% of ovarian malignancies. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) study group has established a clinicopathological database to provide an overview of the current treatment strategies and survival of SCST patients and to identify research needs.<BR><B>METHODS: </B>Twenty centres provided mixed retro- and prospective data of patients with tumour specimens and second-opinion pathology review treated between 2000 and 2014. Descriptive analyses of treatment strategies, Kaplan-Meier curves and cox regression analyses were conducted.<BR><B>RESULTS: </B>Two hundred and sixty-two SCST patients were included. One hundred and ninety-one Granulosa-cell tumour (GCT) and 17 Sertoli-Leydig cell tumour (SLCT) patients were stage I disease (>80%). Forty four GCT (18.7%) and two (8.3%) SLCT patients received adjuvant systemic treatment. After a median observation time of 78.2 months, 46% of all SCST patients experienced disease recurrence, treated predominantly with secondary debulking surgery (> 90%). Advanced FIGO stage, lymph node involvement and intra-operative capsule rupture were associated with disease recurrence on univariate analysis (all p < 0.05). Median OS time was not reached.<BR><B>CONCLUSIONS: </B>In this analysis of SCST patients, adjuvant chemotherapy was unable to prevent disease recurrence. Despite high recurrence rates, overall survival rates were excellent.